Form 4: ADC Therapeutics Director Victor Sandor Disposes of Shares for Tax Obligations

ADC Therapeutics SA Director Victor Sandor reported the disposition of 12,600 common shares at $3.58 per share to cover tax withholding obligations related to the vesting of restricted share units.

Summary

• Victor Sandor, a Director of ADC Therapeutics SA (ADCT), reported a transaction on June 13, 2025.
• The transaction involved the disposition of 12,600 common shares.
• The shares were disposed of at a price of $3.58 per share.
• This disposition was made to satisfy tax withholding obligations incurred from the vesting of previously granted restricted share units (RSUs).
• Following this transaction, Victor Sandor directly beneficially owns 108,286 common shares of ADC Therapeutics SA.

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event related to RSU vesting, which is neutral in sentiment. It is not a discretionary sale or purchase, indicating no specific positive or negative sentiment regarding the company's prospects.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries when restricted stock units or similar equity awards vest. It does not provide specific insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes, not indicative of a change in management's view on the company's value.
• Employees: No direct impact mentioned, but it reflects the standard process for equity compensation vesting and associated tax obligations.

Key Dates

Keywords

ADC Therapeutics, ADCT, Victor Sandor, Form 4, SEC filing, insider transaction, share disposition, tax withholding, restricted share units, RSU vesting, director holdings